1.中国中医科学院中医临床基础医学研究所,北京市东城区东直门内南小街16号,100700
2.中国中医科学院广安门医院
3.北京中医药大学
geyouwen@126.com, (010)64064411
收稿:2021-06-21,
修回:2021-07-26,
纸质出版:2021-10-02
移动端阅览
焦丽雯,郭玉娜,宗星煜等.清肺排毒汤联合西医常规疗法治疗新型冠状病毒肺炎合并2型糖尿病患者49例回顾性临床研究[J].中医杂志,2021,62(19):1709-1714.
JIAO Liwen,GUO Yuna,ZONG Xingyu,et al.Patients with Coronavirus Disease 2019 (COVID-19) and Type 2 Diabetes Treated by Qingfei Paidu Decoction (清肺排毒汤) in Combination with Western Medicine Routine Method:A Retrospective Study of 49 Cases[J].Journal of Traditional Chinese Medicine,2021,62(19):1709-1714.
焦丽雯,郭玉娜,宗星煜等.清肺排毒汤联合西医常规疗法治疗新型冠状病毒肺炎合并2型糖尿病患者49例回顾性临床研究[J].中医杂志,2021,62(19):1709-1714. DOI: 10.13288/j.11-2166/r.2021.19.010.
JIAO Liwen,GUO Yuna,ZONG Xingyu,et al.Patients with Coronavirus Disease 2019 (COVID-19) and Type 2 Diabetes Treated by Qingfei Paidu Decoction (清肺排毒汤) in Combination with Western Medicine Routine Method:A Retrospective Study of 49 Cases[J].Journal of Traditional Chinese Medicine,2021,62(19):1709-1714. DOI: 10.13288/j.11-2166/r.2021.19.010.
目的
2
探讨清肺排毒汤治疗新型冠状病毒肺炎(简称新冠肺炎)合并2型糖尿病的疗效。
方法
2
回顾性收集2020年1月24日至3月17日8个省、自治区、直辖市17家医院确诊的新冠肺炎合并2型糖尿病患者的临床资料,所有患者均服用清肺排毒汤至少6天。比较治疗前及治疗第3天、第6天患者主要临床症状(包括发热、咳嗽、干咳、乏力、厌食、气喘)分布,治疗前及治疗第6天实验室异常指标病例数及肺部病灶分布情况,新型冠状病毒核酸转阴时间及住院时间,记录不良反应发生情况及治疗转归。
结果
2
共纳入新冠肺炎合并2型糖尿病患者49例。与治疗前比较,治疗第3天、第6天有发热、咳嗽、乏力症状的病例数明显减少,差异具有统计学意义(
P
<0.05)。治疗前肺部CT影像结果显示47例患者呈现不同程度的肺部病变,治疗第6天有41例患者呈现不同程度肺部病变,治疗前后肺部病灶分布差异无统计学意义(
P
>0.05)。与治疗前比较,治疗第6天患者C反应蛋白升高、血沉升高、丙氨酸氨基转移酶升高、门冬氨酸氨基转移酶升高、淋巴细胞计数减少、白细胞计数升高的病例数差异均无统计学意义(
P
>0.05)。患者新型冠状病毒核酸转阴时间平均为11(8,15)天,住院时间平均为18(14,23)天,治疗期间未发生严重不良反应,全部患者均痊愈出院。
结论
2
在西医常规治疗基础上联合使用清肺排毒汤可有效缓解新冠肺炎合并2型糖尿病患者发热、咳嗽、乏力等症状,可加快新型冠状病毒核酸转阴,且无严重不良反应,具有较好的预后。
Objective
2
To explore the effect of
Qingfei Paidu Decoction
(清肺排毒汤
QPD) in the treatment of coronavirus disease 2019 (COVID-19) concomitant with type 2 diabetes (T2D).
Methods
2
Clinical data was retrospectively collected from patients confirmed with COVID-19 with T2D and admitted to 17 hospitals in eight provinces/autonomous regions/municipalities from January 24 to March 17
2020. Patients were included if they had taken QPD for at least 6 days. The clinical symptoms (fever
cough
dry cough
fatigue
anorexia
and asthma) were assessed before treatment and at day 3 and day 6 after treatment; the improvement of laboratory abnormal indicators were recorded before treatment and at day 6 after treatment; the time to negative conversion of nucleic acid test result
the duration of hospital stay
adverse reactions
and end-point outcomes were assessed.
Results
2
A total of 49 patients of COVID-19 with T2D were included. Compared to those before treatment
the number of fever
cough and fatigue were significantly reduced at day 3 and day 6 during treatment
and the difference was statistically significant (
P
<0.05). The results of lung CT images showed that 47 patients had different degrees of lung lesions before treatment
and the number decreased to 41 at day 6 during treatment
with no significant difference (
P
>0.05). Compared to those before treatment
the number of patients with elevated C-reactive protein
elevated erythrocyte sedimentation rate
elevated alanine aminotransferase
elevated aspartate aminotransferase
decreased lymphocyte count
and elevated white blood cell count showed no statistically changes at day 6 during treatment (
P
>0.05). The medium time to negative conversion of nucleic acid test result was 11 (8
15) days
and the medium duration of hospital stay was 18 (14
23) days. No serious adverse events occurred during treatment. All patients were cured and discharged from hospitals.
Conclusion
2
The use of QPD in addition to conventional western medicine routine method can effectively alleviate the symptoms of fever
cough
fatigue and other symptoms and promote the negative conversion of nucleic acid test result in COVID-19 patients concomitant with T2D
with no serious adverse reactions and having preferred prognosis.
TADIC M , CUSPIDI C , SALA C . COVID-19 and diabetes: is there enough evidence? [J]. J Clin Hypertens (Greenwich) , 2020 , 22 ( 6 ): 943 - 948 .
国家卫生健康委员会办公厅 , 国家中医药管理局 . 关于推荐在中西医结合救治新型冠状病毒感染的肺炎中使用“清肺排毒汤”的通知 [EB/OL].( 2020-02-07 ) [ 2021-03-20 ]. http://yzs.satcm.gov.cn/zhengcewenjian/2020-02-07/12876.html http://yzs.satcm.gov.cn/zhengcewenjian/2020-02-07/12876.html .
国务院联防联控机制 . 国务院联防联控机制召开新闻发布会:清肺排毒汤是新冠肺炎特效药 [N]. 中国中医药报 , 2020-04-20 (01).
中国疾病预防控制中心 . 新型冠状病毒肺炎流行病学特征分析 [J]. 中华流行病学杂志 , 2020 , 41 ( 2 ): 145 - 151 .
ZHOU Y , CHI J , LV W , et al . Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19) [J]. Diabetes Metab Res Rev , 2021 , 37 ( 2 ): e3377 .
国家卫生健康委员会办公厅 , 国家中医药管理局办公室 . 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第四版)的通知 [EB/QL] .( 2020-01-28 )[ 2021-04-17 ]. http://www.gov.cn/zhengce/zhengceku/2020-01/28/content_5472673.htm http://www.gov.cn/zhengce/zhengceku/2020-01/28/content_5472673.htm .
国家卫生健康委员会办公厅 , 国家中医药管理局办公室 . 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第五版)的通知 [EB/QL].( 2020-02-05 )[ 2021-04-17 ]. http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm .
国家卫生健康委员会办公厅 , 国家中医药管理局办公室 . 关于印发新型冠状病毒肺炎诊疗方案(试行第六版)的通知 [EB/QL].( 2020-02-19 )[ 2021-04-17 ]. http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm .
国家卫生健康委员会办公厅 , 国家中医药管理局办公室 . 关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知 [EB/QL].( 2020-03-04 )[ 2021-04-17 ]. http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm .
American Diabetes Association . Classification and diagnosis of diabetes:standards of medical care in diabetes-2020 [J]. Diabetes Care , 2020 , 43 ( Suppl 1 ): S14 - S31 .
KLEKOTKA RB , MIZGAŁA E , KRÓL W . The etiology of lower respiratory tract infections in people with d iabetes [J]. Pneumonol Alergol Pol , 2015 , 83 ( 5 ): 401 - 408 .
HODGSON K , MORRIS J , BRIDSON T , et al . Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections [J]. Immunology , 2015 , 144 ( 2 ): 171 - 185 .
仝小林 , 倪青 , 魏军平 , 等 . 糖尿病中医诊疗标准 [J]. 世界中西医结合杂志 , 2011 , 6 ( 6 ): 540 - 547 .
修丽梅 , 刘继前 , 尚宪荣 , 等 . 麻黄及其成分对糖尿病改善的探讨 [J]. 中国中医基础医学杂志 , 2011 , 17 ( 10 ): 1102 - 1104 .
薛伯寿 , 姚魁武 , 薛燕星 . “清肺排毒汤”快速有效治疗新型冠状病毒肺炎的中医理论分析 [J]. 中医杂志 , 2020 , 61 ( 6 ): 461 - 462 .
胡小梅 , 耿立梅 , 郭登洲 , 等 . 清肺排毒汤治疗新型冠状病毒肺炎证候分析及疗效观察 [J]. 河北中医 , 2020 , 42 ( 11 ): 1605 - 1609 .
孙易娜 , 吕文亮 , 李昊 , 等 . 清肺排毒汤治疗轻型/普通型新型冠状病毒肺炎295例多中心临床研究 [J]. 中医杂志 , 2021 , 62 ( 7 ): 599 - 603 .
张平 , 潘广涛 . 清肺排毒汤改善新型冠状病毒肺炎危重型患者炎性细胞因子的临床研究 [J]. 世界科学技术-中医药现代化 , 2021 , 23 ( 2 ): 391 - 395 .
0
浏览量
3
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号